Kathleen Meert1, Beth S Slomine2, Faye S Silverstein3, James Christensen2, Rebecca Ichord4, Russell Telford5, Richard Holubkov5, J Michael Dean5, Frank W Moler6. 1. Children's Hospital of Michigan, Wayne State University, 3901 Beaubien Boulevard, Detroit, MI, 48201, USA. Electronic address: kmeert@med.wayne.edu. 2. Kennedy Krieger Institute, Johns Hopkins University, 707 North Broadway, Baltimore, MD, 21205, USA. 3. University of Michigan, Room 8301 MSRB3, Ann Arbor, MI, 48109-5646, USA. 4. Children's Hospital of Philadelphia, University of Pennsylvania, 3410 Civic Center Boulevard, Philadelphia, PA, 19104, USA. 5. University of Utah, 295 Chipeta Way, P.O. Box 581289, Salt Lake City, UT, 84158, USA. 6. CS Mott Children's Hospital, University of Michigan, 1500 East Hospital Drive, Ann Arbor, MI, 48109-5636, USA.
Abstract
OBJECTIVE: To describe one-year cognitive and neurologic outcomes among extracorporeal cardiopulmonary resuscitation (ECPR) survivors enrolled in the Therapeutic Hypothermia after Paediatric Cardiac Arrest In-Hospital (THAPCA-IH) trial; and compare outcomes between survivors who received ECPR, later extracorporeal membrane oxygenation (ECMO), or no ECMO. METHODS: All children recruited to THAPCA-IH were comatose post-arrest. Neurobehavioral function was assessed by caregivers using the Vineland Adaptive Behaviour Scales, 2nd edition (VABS-II) at pre-arrest baseline and 12 months post-arrest. Age-appropriate cognitive performance measures (Mullen Scales of Early Learning or Wechsler Abbreviated Scale of Intelligence) and neurologic examinations were obtained 12 months post-arrest. VABS-II and cognitive performance measures were transformed to standard scores (mean = 100, SD = 15) with higher scores representing better performance. Only children with broadly normal pre-arrest function (VABS-II ≥70) were included in this analysis. RESULTS: One-year follow-up was attained for 127 survivors with pre-arrest VABS-II ≥70. Of these, 57 received ECPR, 14 received ECMO later in their course, and 56 did not receive ECMO. VABS-II assessments were completed at 12 months for 55 (96.5%) ECPR survivors, cognitive testing for 44 (77.2%) and neurologic examination for 47 (82.5%). At 12 months, 39 (70.9%) ECPR survivors had VABS-II scores ≥70. On cognitive testing, 24 (54.6%) had scores ≥70, and on neurologic examination, 28 (59.5%) had no/minimal to mild impairment. Cognitive and neurologic score distributions were similar between ECPR, later ECMO and no ECMO groups. CONCLUSIONS: Many ECPR survivors had favourable outcomes although impairments were common. ECPR survivors had similar outcomes to other survivors who were initially comatose post-arrest.
OBJECTIVE: To describe one-year cognitive and neurologic outcomes among extracorporeal cardiopulmonary resuscitation (ECPR) survivors enrolled in the Therapeutic Hypothermia after Paediatric Cardiac Arrest In-Hospital (THAPCA-IH) trial; and compare outcomes between survivors who received ECPR, later extracorporeal membrane oxygenation (ECMO), or no ECMO. METHODS: All children recruited to THAPCA-IH were comatose post-arrest. Neurobehavioral function was assessed by caregivers using the Vineland Adaptive Behaviour Scales, 2nd edition (VABS-II) at pre-arrest baseline and 12 months post-arrest. Age-appropriate cognitive performance measures (Mullen Scales of Early Learning or Wechsler Abbreviated Scale of Intelligence) and neurologic examinations were obtained 12 months post-arrest. VABS-II and cognitive performance measures were transformed to standard scores (mean = 100, SD = 15) with higher scores representing better performance. Only children with broadly normal pre-arrest function (VABS-II ≥70) were included in this analysis. RESULTS: One-year follow-up was attained for 127 survivors with pre-arrest VABS-II ≥70. Of these, 57 received ECPR, 14 received ECMO later in their course, and 56 did not receive ECMO. VABS-II assessments were completed at 12 months for 55 (96.5%) ECPR survivors, cognitive testing for 44 (77.2%) and neurologic examination for 47 (82.5%). At 12 months, 39 (70.9%) ECPR survivors had VABS-II scores ≥70. On cognitive testing, 24 (54.6%) had scores ≥70, and on neurologic examination, 28 (59.5%) had no/minimal to mild impairment. Cognitive and neurologic score distributions were similar between ECPR, later ECMO and no ECMO groups. CONCLUSIONS: Many ECPR survivors had favourable outcomes although impairments were common. ECPR survivors had similar outcomes to other survivors who were initially comatose post-arrest.
Authors: Rebecca Ichord; Faye S Silverstein; Beth S Slomine; Russell Telford; James Christensen; Richard Holubkov; J Michael Dean; Frank W Moler Journal: Neurology Date: 2018-06-08 Impact factor: 9.910
Authors: Asaad G Beshish; Mathew R Baginski; Thomas J Johnson; Barry K Deatrick; Ryan P Barbaro; Gabe E Owens Journal: Pediatr Crit Care Med Date: 2018-07 Impact factor: 3.624
Authors: Mathias J Holmberg; Guillaume Geri; Sebastian Wiberg; Anne-Marie Guerguerian; Michael W Donnino; Jerry P Nolan; Charles D Deakin; Lars W Andersen Journal: Resuscitation Date: 2018-07-29 Impact factor: 5.262
Authors: Steven A Conrad; L Mikael Broman; Fabio S Taccone; Roberto Lorusso; Maximilian V Malfertheiner; Federico Pappalardo; Matteo Di Nardo; Mirko Belliato; Lorenzo Grazioli; Ryan P Barbaro; D Michael McMullan; Vincent Pellegrino; Daniel Brodie; Melania M Bembea; Eddy Fan; Malaika Mendonca; Rodrigo Diaz; Robert H Bartlett Journal: Am J Respir Crit Care Med Date: 2018-08-15 Impact factor: 21.405
Authors: Ian Jacobs; Vinay Nadkarni; Jan Bahr; Robert A Berg; John E Billi; Leo Bossaert; Pascal Cassan; Ashraf Coovadia; Kate D'Este; Judith Finn; Henry Halperin; Anthony Handley; Johan Herlitz; Robert Hickey; Ahamed Idris; Walter Kloeck; Gregory Luke Larkin; Mary Elizabeth Mancini; Pip Mason; Gregory Mears; Koenraad Monsieurs; William Montgomery; Peter Morley; Graham Nichol; Jerry Nolan; Kazuo Okada; Jeffrey Perlman; Michael Shuster; Petter Andreas Steen; Fritz Sterz; James Tibballs; Sergio Timerman; Tanya Truitt; David Zideman Journal: Resuscitation Date: 2004-12 Impact factor: 5.262
Authors: Murray M Pollack; Richard Holubkov; Penny Glass; J Michael Dean; Kathleen L Meert; Jerry Zimmerman; Kanwaljeet J S Anand; Joseph Carcillo; Christopher J L Newth; Rick Harrison; Douglas F Willson; Carol Nicholson Journal: Pediatrics Date: 2009-07 Impact factor: 7.124
Authors: Kathleen L Meert; Anne-Marie Guerguerian; Ryan Barbaro; Beth S Slomine; James R Christensen; John Berger; Alexis Topjian; Melania Bembea; Sarah Tabbutt; Ericka L Fink; Steven M Schwartz; Vinay M Nadkarni; Russell Telford; J Michael Dean; Frank W Moler Journal: Crit Care Med Date: 2019-03 Impact factor: 7.598
Authors: Beth S Slomine; Faye S Silverstein; James R Christensen; Richard Holubkov; Kent Page; J Michael Dean; Frank W Moler Journal: Pediatrics Date: 2016-03-03 Impact factor: 7.124
Authors: Cydni N Williams; Mary E Hartman; Kristin P Guilliams; Rejean M Guerriero; Juan A Piantino; Christopher C Bosworth; Skyler S Leonard; Kathryn Bradbury; Amanda Wagner; Trevor A Hall Journal: Curr Treat Options Neurol Date: 2019-09-27 Impact factor: 3.598
Authors: Anusha Yeshokumar; Eliza Gordon-Lipkin; Ana Arenivas; Mark Rosenfeld; Kristina Patterson; Raia Blum; Brenda Banwell; Arun Venkatesan; Eric Lancaster; Jessica Panzer; John Probasco Journal: Neurol Neuroimmunol Neuroinflamm Date: 2022-07-06
Authors: Mary E Hartman; Cydni N Williams; Trevor A Hall; Christopher C Bosworth; Juan A Piantino Journal: Pediatr Neurol Date: 2020-02-20 Impact factor: 3.372